Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 1/2012

01-12-2012

Primary hypothyroidism presenting as pseudoacromegaly

Authors: K. V. S. Hari Kumar, Altamash Shaikh, Irfan Anwar, P. Prusty

Published in: Pituitary | Special Issue 1/2012

Login to get access

Abstract

Pseudoacromegaly is a condition characterized by cutaneous manifestations of growth hormone excess but with normal growth hormone levels. This is described in patients with severe insulin resistance, pachydermoperiostitis, burnt out acromegaly and with intake of drugs like Minoxidil. Severe thyroid hormone deficiency rarely present with similar picture and the issue is further complicated in presence of pituitary hyperplasia. We report an unusual presentation of primary hypothyroidism with pseudoacromegaly and thyrotroph hyperplasia mimicking a pituitary macroadenoma. The thyrotroph hyperplasia resolved completely with levothyroxine therapy.
Literature
1.
Ashcraft MW, Hartzband PI, Van Herle AJ, Bersh N, Golde DW (1983) A unique growth factor in patients with acromegaloidism. J Clin Endocrinol Metab 57:272–276PubMedCrossRef
2.
Nguyen KH, Marks JG Jr (2003) Pseudoacromegaly induced by the long term use of minoxidil. J Am Acad Dermatol 48:962–965PubMedCrossRef
3.
Flier JS, Moller DE, Moses AC, O’Rahilly S, Chaiken RL, Grigorescu F, Elahi D, Kahn BB, Weinreb JE, Eastman R (1993) Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 76:1533–1541PubMedCrossRef
4.
5.
Passeri E, Tufano A, Locatelli M, Lania AG, Ambrosi B, Corbetta S (2011) Large pituitary hyperplasia in severe primary hypothyroidism. J Clin Endocrinol Metab 96:22–23PubMedCrossRef
6.
Wittmann AL (1973) Macroglossia in acromegaly and hypothyroidism. Virchows Arch A Pathol Anat Histol 373:353–360CrossRef
7.
8.
9.
Ruchala M, Szczepanek E, Monika Tamborska-Zedlewska M, Czarnywojtek A, Wasko R, Sowinski J (2011) Congenital hypothyroidism simulating acromegaly—a diagnostic pitfall. Neuro Endocrinol Lett 30:322–326
10.
Lim JS, Ku CR, Lee MK, Kim TS, Kim SH, Lee EJ (2010) A case of fugitive acromegaly, initially presented as invasive prolactinoma. Endocrine 38:1–5PubMedCrossRef
Metadata
Title
Primary hypothyroidism presenting as pseudoacromegaly
Authors
K. V. S. Hari Kumar
Altamash Shaikh
Irfan Anwar
P. Prusty
Publication date
01-12-2012
Publisher
Springer US
Published in
Pituitary / Issue Special Issue 1/2012
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-011-0336-x

Other articles of this Special Issue 1/2012

Pituitary 1/2012 Go to the issue

Report

Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report

Report

ACTH-producing remnants following apoplexy of an ACTH-secreting pituitary macroadenoma

Report

Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans’ cell histiocytosis

Report

Desensitization treatment for hypersensitivity reaction to octreotide in an acromegalic patient

Report

Acute cortisol release during stereotactic fractionated radiotherapy to an ACTH-secreting pituitary macroadenoma

Report

Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits